Biotech stocks have always been high-risk and high-reward, with the futures and fortunes of companies often decided with a single successful drug trial or Federal Drug Administration (FDA) approval. The right company can yield extravagant returns for the lucky or prudent investor. However, choosing the wrong ones can lead to losses just as significant as the potential wins. Therefore, due diligence is important. A company announcing that it is developing a cure for cancer, MS, Huntington’s, or HIV is not en ...

MAINZ, Germany, March 6, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via ...

公司业绩公布 - BioNTech将于2024年3月20日公布2023年全年和第四季度的财务业绩[1] - 公司将在当天举行电话会议和网络直播，讨论财务业绩并提供公司更新[1] 公司介绍 - BioNTech是一家新一代免疫疗法公司，致力于开发癌症和其他严重疾病的新疗法[4] - 公司拥有广泛的肿瘤产品候选药物组合，包括个性化和现成的mRNA疗法、创新的嵌合抗原受体T细胞、双特异性免疫检查点调节剂、靶向癌症抗体和小分子药物[4]

制药行业发展 - 制药行业近年来发展了一些重磅产品，包括新型疫苗和减肥药物，这使得投资者越来越看好制药股作为一个有前景的增长行业[1] 爱力李莉（LLY）股票 - 爱力李莉（LLY）股票在过去五年中上涨了440%，主要得益于其针对糖尿病和肥胖症的药物取得了巨大成功，预计2023年全年总收入将达到340亿美元[3][4] - 爱力李莉的增长可能会继续，但目前的估值已经脱离了现实，股价已经达到了2023年收入的100倍，一旦减肥药市场放缓，股价可能会急剧下跌[6] BioNTech SE（BNTX） - BioNTech SE（BNTX）在2020年之前几乎没有营业收入，但随着COVID-19疫苗的出现，公司的命运发生了改变，但随着对COVID-19疫苗的兴趣急剧下降，公司的收入从2021年的216亿美元下降到2023年的不到50亿美元，预计2024年将再次下降，公司的盈利能力大幅减弱，分析师预测2024年的市盈率将达到93倍，公司难以将疫苗利润转化为更可持续的收入流，这可能导致股价急剧下跌[9][10][11] 默克（MRK） - 默克（MRK）股价自11月28日以来上涨了25%，公司拥有一种领先的癌症药物Keytruda，但分析师认为公司的股价已经明显高估，目前的股价已经包含了Keytruda的成功，同时，肿瘤学领域的竞争也对默克的中期前景构成了重大风险[12][13][14][15]

Designation is based on preliminary safety and efficacy data from an ongoing Phase 1/2 trial in patients with platinum-resistant ovarian epithelial cancer, fallopian tube, or primary peritoneal cancer1 Fast Track designation can facilitate the development and expedite the regulatory review of BNT325/DB- 1305 Ovarian cancer is the fourth most common gynecological tumor type2 with over 300,000 cases diagnosed globally each year3; over 90% of ovarian tumors arise from epithelial cells, including the epithelial ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in BioNTech stock or options between March 30, 2022 and October 13, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BNTX. ...

试验详情 - BioNTech和DualityBio宣布启动了一项关键的第三阶段试验，评估下一代抗体药物结合物BNT323/DB-1303的疗效和安全性[2] - 该试验将评估BNT323/DB-1303与标准单药化疗在化疗前患有HR+和HER2低表达转移性乳腺癌的患者中的疗效和安全性[3] 药物特点 - BNT323/DB-1303是一个第三代拓扑异构酶-1抑制剂基于ADC，针对HER2，已在HER2阳性和HER2低表达肿瘤模型中展示了抗肿瘤活性[8] - BNT323/DB-1303的设计目的是结合抗体的选择性和化疗的肿瘤细胞杀伤性，旨在减少化疗药物对患者的毒性[4]

SHANGHAI, Jan. 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that its Research Service Unit (R in CRDMO) has signed a research service agreement with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. Under the terms of the agreement, WuXi Biologics leverages its proprietary antibody discover ...

公司业绩 - BioNTech成立15年，首个COVID-19疫苗已发货4.5亿剂，2023年交付4亿剂[3] - 目前有27个临床项目，20个在肿瘤领域，11个处于II期和III期[4] - 2023年公司新增1600名员工，现有资产超过170亿美元[5] 新产品和技术研发 - 与合作伙伴辉瑞合作开发评估各种呼吸道疾病的疫苗组合，已开始III期临床试验[6] - 公司在非洲基加利建立了首个mRNA制造设施，计划每年生产1500万剂mRNA疫苗[7] - 公司计划在2024年报告所有临床试验数据，部分项目进入II期[7] 市场扩张和并购 - 公司在2023年着重收购了ADC领域的新资产，计划在2025年和2026年推出新的ADC产品[10] - 公司的策略是通过收购资产来覆盖尽可能多的适应症，ADC将成为所有适应症的癌症的主要治疗方法[11] 未来展望 - 公司计划在2024年开始注册试验，以加速上市的分子，并计划在2025年至2029年推出多个肿瘤产品[14] - 公司的长期愿景是在2025年至2029年推出多个产品，并在传染病领域和新疾病领域进行扩展[14]

BioNTech SE (NASDAQ:BNTX) 42nd Annual J.P. Morgan Healthcare Conference January 9, 2024 12:00 PM ET Company Participants Ugur Sahin - CEO Ryan Richardson - Chief Strategy Officer Conference Call Participants Jess Fye - J.P. Morgan Jess Fye Great. Good morning, everyone. My name is Jess Fye. I am a Senior Biotech Analyst at J.P. Morgan, and we’re continuing the conference today with BioNTech. I am joined by the company's CEO, Dr. Ugur Sahin. He is going to give a presentation on the company and then we are g ...